OptiNose, Inc. provided earnings guidance for the full year 2025. for the year, the company expects peak XHANCE net revenues to exceed $300 million based on its current promotional focus on a specialty audience of mostly ENT and Allergy specialists. The company also expects to produce positive income from operations (GAAP) for full year 2025.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.08 USD | +0.93% | -2.70% | -16.28% |
May. 20 | OptiNose, Inc. announced that it has received $4.68 million in funding | CI |
May. 14 | Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.28% | 156M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025